Immuneering Corp (IMRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.48 (+0.45%), Market cap $0.33B, 52-week low–high $1.44 ~ $9.26.
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RA
Financial statements, price targets, institutional (13F) holdings and related news for Immuneering Corp are updated in real time on BlackAll Trade.
Immuneering Corp trades at $4.48 (+0.45%). Real-time quotes and charts are available on BlackAll Trade.
Immuneering Corp has a market cap of about $0.33B.
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhi